OncoMed Pharmaceuticals (OMED) has multiple early-stage cancer antibodies in its pipeline that are wholly owned or partnered with GlaxoSmithKline plc (GSK) and Bayer AG (FRA:BAYN) that could drive the stock to the upside by over 50%, says Ted Tenthoff, Managing Director and Senior Research Analyst at Piper Jaffray & Co.
“[OncoMed] was a recent IPO this year, and this company is also an antibody-development company or a biotherapeutic company, and they are developing cancer antibodies, and they presently have five early-stage cancer antibodies that are wholly owned and/or partnered with two of the leading pharmaceutical companies, GSK and Bayer. And the really — this is a company that went public at $17 in July, ran all the way up to $31 in its first-day trading, and it’s kind of settled back down around maybe even below that IPO price,” Tenthoff said.
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
Although the company has a higher risk profile than average, Tenthoff says OMED has the potential to move back up to around $30 after revealing data at a large meeting in October that could validate the effectiveness of its oncology solution.
“Here I think the valuation is very attractive, trading around $0.5 billion, which for multiple antibodies in the clinic, again, it could represent — we have a $30 price target on it currently, which is over a 50% move, but I think they’re going to have some data at a big scientific meeting in October that could really validate their pipeline, and I think create a lot of value,” Tenthoff said.
Apple (AAPL)’s Sustained Cash Flow of $50 Billion Could Raise Dividends, Increase Stock Buybacks
March 14, 2013
Banks Able to Raise Capital Face Creative Challenges to ROE
April 08, 2010
Teleflex Incorporated (TFX) Expected to Raise Operating Margin for Single-Use Medical Products
August 07, 2013
The Home Depot, Inc. (HD) Positioned to Raise Dividend Up to 14% After 20%-Plus Increase in 2014
April 29, 2014
Bombardier (TSE:BBD.B) CSeries Success Could Triple BBD’s Stock Value Over the Next Five Years
May 28, 2013
